Project Details
Description
Project Summary
HSV-1 causes lifelong infections in millions of people in the USA and around the world. Natural infections of
HSV-1 follow a cycle of productive replication in epithelial cells, followed by transit into nerve endings, and
establishment of a lifelong viral reservoir in neurons. Despite high demand and many efforts to design a
HSV-1 vaccine, prior candidates have failed in human trials after showing promise in animal models. This
efficacy gap reflects our incomplete understanding of how this virus responds to selective pressures in
cellular and animal models – e.g. during vaccine development – and in vivo during human infections. Here
we propose to use an experimental evolution approach to reveal how HSV-1 adapts to key cellular niches
such as fibroblasts and neurons, and to altered levels of interferon signaling, as a key component of host
immunity. These studies will utilize a unique resource of sequential cultured isolates from newly-infected
individuals, to enable a new level of comparison between experimental and natural evolutionary pressures.
In Aim 1, we will explore HSV-1 evolution in the distinct cellular niches of human fibroblasts and neurons.
As part of an ongoing collaboration, we have access to a unique repository of sequential clinical HSV-1
isolates from immunocompetent individuals in the first year of their infection. Using the initial virus isolates
from these individuals, we will carry out experimental evolution in primary human fibroblasts and human
neurons, which represent the two key cellular niches of infection in vivo. We will deep sequence the viral
populations of replicate lineages from experimental evolution in either fibroblasts, neurons, or alternating
between the two cell types. The genetic variations that arise in each viral population over time will be
analyzed using statistical models to differentiate genetic drift from directional selection. Variants observed
during experimental evolution in these defined environments will then be compared to those detected in the
course of natural evolution, via sequential viral cultures from the same infected individuals.
The interferon response is a critical aspect of host immune control of infection. Multiple HSV-1 genes have
been implicated in viral antagonism of the host interferon response, although these are traditionally studied
one at a time. In Aim 2, we will use the experimental evolution approach to conduct an unbiased, genome-
wide screen for genetic loci involved in interferon antagonism by HSV-1. By treating primary human
fibroblasts with either exogenous interferon, or with antibodies to deplete interferon production, we will
evolve HSV-1 in a heightened or depleted antiviral state, respectively. After sequencing replicate lineages of
these evolved viral populations, we will use patterns of genetic drift and/or positive selection to identify
viral genes associated with interferon antagonism. Together these experimental evolution data will provide
new insights on how HSV-1 adapts to these distinct cellular niches, and shed new light on the complex
interplay of selective pressures found in natural infections.
Status | Finished |
---|---|
Effective start/end date | 5/6/22 → 4/30/24 |
Funding
- National Institute of Allergy and Infectious Diseases: $196,865.00
- National Institute of Allergy and Infectious Diseases: $236,412.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.